Suppr超能文献

关于使用口服核苷(酸)类似物阻断高病毒载量HBV携带者孕妇母婴传播的思考

[Considerations of using oral nucleos(t)ide analogues to interrupt mother-to-child transmission in HBV carrier pregnant woman with high viral load].

作者信息

Ding Y, Sheng Q J, Dou X G

机构信息

Department. of Infectious Disease, Shengjing Hospital of China Medical University, Shenyang 110022, China.

出版信息

Zhonghua Gan Zang Bing Za Zhi. 2019 Feb 20;27(2):85-87. doi: 10.3760/cma.j.issn.1007-3418.2019.02.002.

Abstract

The main transmission route of chronic hepatitis B virus infection is mother-to-child transmission of hepatitis B virus and the main cause of combined immune prophylaxis failure in neonates at the end of pregnancy is high viral load. Moreover, oral administration of nucleos(t)ide analogues (NAs) during the second and third trimesters of pregnancy can significantly reduce or even completely block mother-to-child transmission of HBV. This article focuses on the necessity and feasibility of oral NAs antiviral therapy for HBV carrier pregnant woman with high viral load, and the issues commences at the time of medication and viral load thresholds.

摘要

慢性乙型肝炎病毒感染的主要传播途径是乙肝病毒母婴传播,妊娠末期新生儿联合免疫预防失败的主要原因是病毒载量高。此外,在妊娠中期和晚期口服核苷(酸)类似物(NAs)可显著降低甚至完全阻断HBV母婴传播。本文重点探讨了高病毒载量的HBV携带孕妇口服NAs抗病毒治疗的必要性和可行性,以及用药时机和病毒载量阈值等问题。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验